The FDA Grants Fast Track Designation For Kymera Therapeutics' KT-621 For Moderate to Severe Asthma

Benzinga Newsdesk www.benzinga.com Positive 75.1%

Neg 0% Neu 0% Pos 75.1%

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027
KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027
Fast Track designation previously granted for KT-621 for moderate to severe AD

Comments

No comments yet. Be the first!

The FDA Grants Fast Track Designation For Kymera Therapeutics&#39; KT-621 For Moderate to Severe Asthma